RxDoctor Payments Data

Jeffrey Fuller, MD

Retina Specialist · Birmingham, ALNPI 1356343917

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,400 of the $14,776 with a category attached, or 77.2%. 15 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 58.2% of the total. Reporting peaked in 2019 at $8,439 and has fallen 92.1% since, to $670 in 2025. Among retina specialist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,776in general payments, 2019–2025

Across 129 payments — averaging $114.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$9K
  • Novartis$3K
  • AbbVie$884
  • Genentech USA, Inc.$572
  • Astellas Pharma US Inc$389
  • Apellis Pharmaceuticals, Inc.$186
  • plus $682 from 9 others

What the payments were for

  • Consulting fees$11,40077%
  • Travel & lodging$180%
  • Food & beverage$3,35823%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,776 in reported general payments places this provider in the 95th percentile of 21 retina specialist providers in Alabama.

See all retina specialist providers in Alabama

Medicare billing

Part B allowed, 2024
$4,448,620
Medicare patients
745
Services billed
57,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium31$11,679
CombiganBrimonidine Tartrate/Timolol21$6,092
Prednisolone Acetate164$5,077
LumiganBimatoprost17$4,793
Brimonidine Tartrate59$4,438
Ketorolac Tromethamine168$3,921
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha101$1,383
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat69$1,268
Latanoprost110$963
Dorzolamide Hcl21$642
Difluprednate14$566
Timolol Maleate64$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan$884$10,88538 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 retina specialist providers in Alabama.

Other retina specialist in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →